B74/100

Is Humana (HUM) a risky stock?

Sector: Health Care Price: $403.79 Composite: 74/100

As of July 21, 2026, Clavix grades Humana (HUM) B for risk, a composite score of 74 out of 100 on an A+ to F scale, which puts HUM in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.

Grade as of July 21, 2026. Clavix regrades every trading day.

The five risk dimensions behind HUM's grade

Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how HUM scores on each, as of July 21, 2026.

Financial healthbalance sheet, margins, cash flow
65
News sentimentscored, sourced recent coverage
64
Macro exposuresensitivity to rates, dollar, oil
68
Sector resiliencestrength vs the broad market
75
Price stabilitydrawdown and volatility
42

What's moving HUM's risk right now

Company-specific signals Clavix flags behind HUM's current grade, drawn from recent news and filings as of July 21, 2026.

Regulatory · mixed signal

HUM likely benefited from a sympathy rally as positive managed-care sector news signal from UNH's earnings spilled over to peers, though the faltering UNH breakout suggests the sect…

Earnings & results · mixed signal

The sticker price on CVS shares looks high, but the real question is what it costs on the earnings expected two years from now.

What a B grade means

On the Clavix A+ to F scale, HUM's composite of 74 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.

A+AA-B+BB-C+CC-D+DD-F
Get Clavix on iPhone → Or grade your whole portfolio free, no account needed.

This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell HUM or any security. Grades are risk indicators, not predictions of return. Data may be delayed.